Triple-negative breast cancer trials in Malaysia
3 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Where
- Kuala Lumpur, Kuching, Putrajaya
- Age
- 18 years and over
- People
- 1,000 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06841354 · EU 2024-516834-36-00 - Phase 3Taking peopleA Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Where
- George Town, Kuala Lumpur, Kuching, Lembah Pantai, Putrajaya
- Age
- 18 years and over
- People
- 2,400 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06966700 · EU 2024-520190-12-00 - Phase 3Taking peopleSacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Where
- Kuala Lumpur
- Age
- 18 years and over
- People
- 1,530 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06393374 · EU 2023-504962-52-00